Abstract-The authentic standards 2-(cyclopropanecarboxamido)-N-(4-methoxypyridin-3-yl)isonicotinamide (4a) and 2-(cyclopropanecarboxamido)-N-(4-(4-methoxyphenyl)pyridin-3-yl)isonicotinamide (7a), and their corresponding precursors 2-(cyclopropanecarboxamido)-N-(4-hydroxypyridin-3-yl)isonicotinamide (4b) and 2-(cyclopropanecarboxamido)-N-(4-(4-hydroxyphenyl)pyridin-3-yl)isonicotinamide (7b) were synthesized from methyl 2-aminoisonicotinate and cyclopropanecarbonyl chloride with overall chemical yield 47% in three steps, 22% in four steps, 40% in three steps, and 17% in four steps, respectively. 11 C]methylation and isolated by HPLC combined with SPE in 40-50% radiochemical yield, based on [ 11 C]CO2 and decay corrected to end of bombardment (EOB). The radiochemical purity was >99%, and the specific activity (SA) at EOB was 370-1110 GBq/µmol with a total synthesis time of ~40-minutes from EOB.
Alzheimer's disease (AD) is the most common form of dementia and affects over 30 million people worldwide, and there are no reliable disease-modifying therapies at present. [1] [2] [3] [4] Currently, the cause of AD remains unclear and no any effective strategy is approved for preventing, curing and slowing the progress of AD. [5] [6] [7] To discover more effective treatments, a reliable diagnostic tool is really needed. 8 Neuroimaging of AD is one of the most active as well as most challenging areas in neuroscience. 9 Advanced biomedical imaging technique positron emission tomography (PET) is a promising modality for AD, and significant advances have accomplished in this field of molecular imaging. 10 The development of PET imaging probes for in vivo detection of Alzheimer's brains is critical for early and accurate diagnosis and for the successful discovery of disease-modifying therapies. [11] [12] [13] Currently, aggregated β-amyloid plaques (Aβ) and tau protein are two major biomarkers for AD. 14 17 as displayed in Figure 1 , the representative PET tau tracers include [ 11 19 ( Figure 1 ), and promising clinical PET imaging results with these tracers have been reported.
The success and limitations of Aβ imaging and tau imaging have spurred efforts worldwide to develop new selective PET tracers for different imaging targets, and glycogen synthase kinase-3 (GSK-3) has become a novel and attractive molecular target for treatment and PET imaging of AD. 20 The enzyme GSK-3 is a serine/threonine protein kinase, which exists as two isoforms GSK-3α and GSK-3β. GSK-3 plays an important role in a number of diverse cellular processes including metabolism, differentiation, proliferation, and ___________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Gao 1 Subsequent treatment with KOH in methanol and water achieved complete conversion to acylated acid 2, which upon neutralization with aqueous HCl precipitated out as a white solid in 98% yield. The acid 2 could directly reacted 3-aminopyridines 3a,b under corresponding amide formation conditions or be firstly converted to the acid chloride with oxalyl chloride then to react with 3-aminopyridines 3a,b, to give the product isonicotinamides 4a,b in 55% and 46% yield, respectively. 26, 27 in acetonitrile at 80 °C under basic conditions (2 N NaOH). The product was isolated by semi-preparative reverse-phase (RP) high performance liquid chromatography (HPLC) with a C-18 column, and then concentrated by solid-phase extraction (SPE) [28] [29] [30] with a disposable C-18 Light Sep-Pak cartridge to produce the corresponding pure radiolabeled compound 32 Overall, it took ~40 min for synthesis, purification and dose formulation.
The radiosynthesis was performed in a home-built automated multi-purpose [ 11 C]-radiosynthesis module. [33] [34] [35] This radiosynthesis module facilitated the overall design of the reaction, purification and reformulation capabilities in a fashion suitable for adaptation to preparation of human doses. In addition, the module is designed to allow in-process measurement of [
11 C]-tracer specific activity (SA, GBq/µmol at EOB) using a radiation detector at the outlet of the HPLCportion of the system. For the reported syntheses, product SA was in a range of 370-1110 GBq/µmol at EOB. The factors that affect the EOB SA significantly to lead to such a wide range from 370 to 1110 GBq/µmol are mainly from two parts: (1) 38 calculated, decay corrected to EOB, and based on [ 11 C]CO2, which was in agreement with the 'on line' determined value. In each our [ 11 C]-tracer production, if semi-preparative HPLC was used for purification, then the SA of [ 11 C]-tracer was assessed by both semi-preparative HPLC (during synthesis) and analytical HPLC (EOS); if SPE was used for purification, then the SA of [ 11 C]-tracer was only measured by analytical HPLC at EOS. 25 Chemical purity and radiochemical purity were determined by analytical HPLC. 38 The chemical purity of the precursors and reference standard was >90%. The radiochemical purity of the target tracer was >99% determined by radio-HPLC through γ-ray (PIN diode) flow detector, and the chemical purity of the target tracer was >90% determined by reversed-phase HPLC through UV flow detector.
The experimental details and characterization data for compounds 1, 2, 4a,b, 5, and 7a, 11 C]methylation at the pyridinyl hydroxyl or phenyl hydroxyl position of the desmethyl precursor, followed by product purification and isolation using a semi-preparative RP HPLC combined with SPE. The carbon-11-labeled isonicotinamides were obtained in high radiochemical yield, radiochemical purity and chemical purity, with a reasonably short overall synthesis time, and high specific activity. This will facilitate studies to evaluate carbon-11-labeled isonicotinamides as new potential PET agents for imaging of GSK-3 enzyme in AD. procedure. 27 Melting points were determined on a MEL-TEMP II capillary tube apparatus and were uncorrected. (Hz) . Liquid chromatographymass spectra (LC-MS) analysis was performed on an Agilent system, consisting of an 1100 series HPLC connected to a diode array detector and a 1946D mass spectrometer configured for positive-ion/negative-ion electrospray ionization. The high resolution mass spectra (HRMS) were obtained using a Waters/Micromass LCT Classic spectrometer. Chromatographic solvent proportions are indicated as volume: volume ratio. Thin-layer chromatography (TLC) was run using Analtech silica gel GF uniplates (5 × 10 cm 2 ). Plates were visualized under UV light. Preparative TLC was run using Analtech silica gel UV254 plates (20 × 20 cm 2 ). Normal phase flash column chromatography was carried out on EM Science silica gel 60 (230-400 mesh) with a forced flow of the indicated solvent system in the proportions described below. All moisture-and air-sensitive reactions were performed under a positive pressure of nitrogen maintained by a direct line from a nitrogen source. Analytical RP HPLC was performed using a Prodigy (Phenomenex) 5 µm C-18 column, 4.6 × 250 mm; mobile phase 15% CH3CN/85% H2O/0.1% TFA for 4a,b and 30% CH3CN/70% 20 mM H3PO4 for 7a,b; flow rate 1.3 mL/min for 4a,b and 1.0 mL/min for 7a,b; UV (254 nm) and γ-ray (PIN diode) flow detectors. Semi-preparative RP HPLC was performed using a Prodigy (Phenomenex) 5 µm C-18 column, 10 × 250 mm; mobile phase 15% CH3CN/85% H2O/0.1% TFA for 4a,b and 30% CH3CN/70% 20 mM H3PO4 for 7a,b; flow rate 7 mL/min for 4a,b and 4 mL/min for 7a,b; UV (254 nm) and γ-ray (PIN diode) flow detectors. C18 Light Sep-Pak cartridges were obtained from Waters Corporation (Milford, MA). Sterile Millex-FG 0.2 µm filter units were obtained from Millipore Corporation (Bedford, MA).
(b).
Methyl 2-(cyclopropanecarboxamido)isonicotinate (1) : To a solution of methyl 2-aminoisonicotinate (18.25 g, 120 mmol) in pyridine (200 mL) was added cyclopropanecarbonyl chloride (15.16 g, 145 mmol) at 0 °C. After stirring at 0 °C for 3 h, the reaction mixture was poured into cold 5 N aqueous HCl (500 mL) solution and stirred. The resulting precipitate was filtered, washed with cold water, and dried to give a white solid product 1 (22.08 g). The filtrate was extracted with EtOAc (3 × 100 mL), washed with water, brine, dried over Na2SO4, and concentrated in vacuo, The residue was purified by column chromatography on silica gel with eluent ( 
2-(Cyclopropanecarboxamido)-N-(4-methoxypyridin-3-yl)isonicotinamide (4a):
To a 250 mL flask was added compound 2 (206 mg, 1.0 mmol) in CH2Cl2 (20 mL) to give a white suspension. After cooling to 0 °C, oxalyl chloride (0.3 g) and DMF (2 drops) were added. The mixture was stirred at 0 °C for 1 h, then the mixture was evaporated in vacuo. A solution of 4-methoxypyridin-3-amine (3a, 124 mg, 1.0 mmol) in CH2Cl2 (5 mL) was added into above mixture at 0 °C, followed by N,Ndiisopropylethylamine (DIPEA, 260 mg, 2.0 mmol). After stirring at RT for 2 h, the reaction mixture was concentrated under reduced pressure to give a tan oil.
The residue was purified by column chromatography on silica gel with eluent (3:97 MeOH/CH2Cl2) to give a white solid product 4a (164 mg, 55% 
f). 2-(Cyclopropanecarboxamido)-N-(4-iodopyridin-3-yl)isonicotinamide (5):
Compound 5 was prepared from compound 2 with 4-iodopyridin-3-amine using the same procedure as described for the synthesis of 4a as a yellow solid, yield 41%. Rf = 0.70 (1:9 MeOH/CH2Cl2), mp 156-158 °C. 
2-(Cyclopropanecarboxamido)-N-(4-(4-methoxyphenyl)pyridin-3-yl)isonicotinamide (7a):
To a suspension of compound 5 (82 mg, 0.2 mmol), (4-methoxyphenyl)boronic acid (6a, 46 mg, 0.3 mmol), and Na2CO3 (53 mg, 0.5 mmol) in dioxane (50 mL) was added tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02 mmol). The reaction mixture was subsequently heated at 110 °C for 15 h. After the reaction was cooled down, it was filtered through Celite, washed with dioxane, and concentrated in vacuo. The resultant residue was purified by column chromatography on silica gel with eluent (2:98 MeOH/CH2Cl2) to give a white solid product 7a (49 mg, 63%). Rf 
